RenovoRx, Inc.
NASDAQ:RNXTBiotechnology
-$0.01 today
- Market cap
- $54.04M
- Beta
- 0.99
- P/E (TTM)
- -3.4
- EPS (TTM)
- -$0.32
Volume 0.84M
Average 0.29M
RNXT Total Current Assets
All assets expected to be converted to cash or used up within one year.
RenovoRx, Inc.NASDAQ: RNXT
Total Current Assets · Q1 FY2026 · quarter ended Mar 2026
Total current assets falls 12.9% from a year ago
Total current assets stood at $13.72M at the end of Q1 FY2026, down 12.9% from a year earlier and up 73.8% from the prior quarter. Over 3 fiscal years it compounded at +2.8% a year.
Context
- Total current assets amounted to 98.3% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Total current assets increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current assets keeps falling in the next quarterly balance sheet after a -12.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 7.89M USD
- Year-over-year change
- +0.8%
- 4-year CAGR
- -16.6%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.89M | +0.8% |
| FY2024 | 2024-12-31 | 7.83M | +434.0% |
| FY2023 | 2023-12-31 | 1.47M | -79.8% |
| FY2022 | 2022-12-31 | 7.27M | -55.4% |
| FY2021 | 2021-12-31 | 16.28M | — |
Total Current Assets vs competitors
How RNXT compares with its peers on the latest reported figures
- RNXT's Mar 2026 total current assets of $13.72M is the 3rd highest of the 6 companies compared; the peer median is $12.56M.
- Its year-over-year change of -12.9% is the 3rd highest of 6, against a peer median of -39.2%.
- Total current assets amounts to 98.3% of total assets for RNXT, versus a peer median of 97.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $35.32M | +197.7% | -6.3% | 100.0% | |
| Mar 2026 | $16.24M | -39.2% | -16.4% | 100.0% | |
| Mar 2026 | $13.72M | -12.9% | +2.8% | 98.3% | |
| Mar 2026 | $12.56M | +43.2% | +2.4% | 65.6% | |
| Dec 2025 | $12.32M | -40.1% | -28.4% | 11.5% | |
| Mar 2026 | $7.06M | -66.1% | +468.7% | 97.7% | |
| Peer median (excluding RNXT) | $12.56M | -39.2% | -6.3% | 97.7% | |
Competitors are the stored peer set for RNXT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
RenovoRx, Inc.
NASDAQ:RNXT
Intrinsic Alpha fair value
Locked
Current Price
$1.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.